$TFFP
TFF Pharmaceuticals, Inc. Stock $tffp

$tffp Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024027185 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$203.3K	$114.3K	$733.9K
YoY Change	295.25%	-63.45%	48.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.438M	$2.509M	$10.57M
YoY Change	-21.83%	-29.48%	-23.41%
% of Gross Profit
Research & Development	$3.556M	$2.974M	$12.06M
YoY Change	14176.56%	-28.09%	-34.79%
% of Gross Profit
Depreciation & Amortization	$140.2K	$130.7K	$502.5K
YoY Change	13.82%	8.07%	29.43%
% of Gross Profit
Operating Expenses	$5.994M	$5.483M	$22.63M
YoY Change	-16.02%	-28.73%	-29.93%
Operating Profit	-$5.791M		-$21.89M
YoY Change	-18.28%		-31.14%
Interest Expense	$15.61K	$606.3K	$651.4K
YoY Change	-55.49%	7940.98%	2337.07%
% of Operating Profit
Other Income/Expense, Net	$55.75K		$651.4K
YoY Change	58.92%		2337.26%
Pretax Income	-$5.735M	-$4.762M	-$21.24M
YoY Change	-18.67%	-35.41%	-33.13%
Income Tax
% Of Pretax Income
Net Earnings	-$5.700M	-$4.762M	-$21.24M
YoY Change	-19.16%	-35.41%	-33.13%
Net Earnings / Revenue	-2804.11%	-4165.49%	-2894.69%
Basic Earnings Per Share	-$2.40		-$11.85
Diluted Earnings Per Share	-$2.40	-$2.01	-$11.85
COMMON SHARES
Basic Shares Outstanding	2.519M shares	59.13M shares	1.793M shares
Diluted Shares Outstanding	2.388M shares		1.793M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.212M	$5.478M	$5.478M
YoY Change	-73.71%	-67.02%	-67.02%
Cash & Equivalents	$3.200M	$5.478M	$5.478M
Short-Term Investments
Other Short-Term Assets	$1.363M	$1.678M	$1.678M
YoY Change	-12.37%	-24.61%	-24.61%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$4.863M	$7.590M	$7.590M
YoY Change	-65.17%	-60.1%	-60.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.880M	$2.119M	$2.119M
YoY Change	-15.57%	-31.15%	-35.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$7.690K	$7.690K	$7.690K
YoY Change	0.03%	0.03%	0.0%
Total Long-Term Assets	$4.324M	$4.437M	$4.437M
YoY Change	1.71%	-12.92%	-12.92%
TOTAL ASSETS
Total Short-Term Assets	$4.863M	$7.590M	$7.590M
Total Long-Term Assets	$4.324M	$4.437M	$4.437M
Total Assets	$9.187M	$12.03M	$12.03M
YoY Change	-49.56%	-50.14%	-50.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.664M	$958.4K	$958.4K
YoY Change	23.74%	4.22%	4.22%
Accrued Expenses	$1.983M	$1.369M	$1.369M
YoY Change	2336.34%	1509.57%	1509.57%
Deferred Revenue		$101.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.871M	$2.429M	$2.429M
YoY Change	145.51%	114.79%	114.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$10.86K	$31.74K	$31.74K
YoY Change	-88.13%	-71.17%	-71.17%
Total Long-Term Liabilities	$10.86K	$31.74K	$31.74K
YoY Change	-88.13%	-71.17%	-71.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.871M	$2.429M	$2.429M
Total Long-Term Liabilities	$10.86K	$31.74K	$31.74K
Total Liabilities	$3.882M	$2.460M	$2.460M
YoY Change	132.69%	98.29%	98.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$124.1M	-$118.3M
YoY Change	19.17%	21.85%
Common Stock	$129.6M	$128.0M
YoY Change	357911.24%	353689.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.304M	$9.567M	$9.567M
YoY Change
Total Liabilities & Shareholders Equity	$9.187M	$12.03M	$12.03M
YoY Change	-49.56%	-50.14%	-50.14%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$5.700M	-$4.762M	-$21.24M
YoY Change	-19.16%	-35.41%	-33.13%
Depreciation, Depletion And Amortization	$140.2K	$130.7K	$502.5K
YoY Change	13.82%	8.07%	29.43%
Cash From Operating Activities	-$3.144M	-$4.214M	-$16.04M
YoY Change	-27.98%	-45.29%	-41.34%
INVESTING ACTIVITIES
Capital Expenditures		$46.39K	$94.75K
YoY Change		-67.14%	-93.89%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$46.39K	-$94.75K
YoY Change		-67.14%	-93.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$5.122M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$901.1K	560.0	5.013M
YoY Change	-5128.68%	-100.0%	-57.34%
NET CHANGE
Cash From Operating Activities	-$3.144M	-4.214M	-16.04M
Cash From Investing Activities		-46.39K	-94.75K
Cash From Financing Activities	$901.1K	560.0	5.013M
Net Change In Cash	-$2.266M	-4.259M	-11.12M
YoY Change	-48.45%	-221.94%	-35.29%
FREE CASH FLOW
Cash From Operating Activities	-$3.144M	-$4.214M	-$16.04M
Capital Expenditures		$46.39K	$94.75K
Free Cash Flow		-$4.260M	-$16.13M
YoY Change		-45.68%	-44.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2022	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1199191	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-11.85
CY2022	tffp	Change In Fair Value Of Note Receivable ChangeInFairValueOfNoteReceivable		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-26.49
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39102
CY2023	dei	Entity Registrant Name EntityRegistrantName	TFF Pharmaceuticals, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1751 River Run
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Fort Worth
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	76107
CY2023	dei	City Area Code CityAreaCode	(817)
CY2023	dei	Local Phone Number LocalPhoneNumber	438-6168
CY2023	dei	Security12b Title Security12bTitle	Common stock: Par value $0.001
CY2023	dei	Trading Symbol TradingSymbol	TFFP
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	16500000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2519220	shares
CY2023	dei	Auditor Name AuditorName	Marcum llp
CY2023	dei	Auditor Location AuditorLocation	New York, NY
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5478113	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16612315	usd
CY2023Q4	tffp	Research And Development Tax Incentive Receivable ResearchAndDevelopmentTaxIncentiveReceivable	433852	usd
CY2022Q4	tffp	Research And Development Tax Incentive Receivable ResearchAndDevelopmentTaxIncentiveReceivable	186507	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1678353	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2226344	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	7590318	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	19025166	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	119529	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	196044	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1999781	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3078342	usd
CY2023Q4	us-gaap	Notes Receivable Fair Value Disclosure NotesReceivableFairValueDisclosure	2310000	usd
CY2022Q4	us-gaap	Notes Receivable Fair Value Disclosure NotesReceivableFairValueDisclosure	1812975	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7688	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7688	usd
CY2023Q4	us-gaap	Assets Assets	12027316	usd
CY2022Q4	us-gaap	Assets Assets	24120215	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	958442	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	919607	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1285586	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4430	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	101000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	126000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	83512	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	80625	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2428540	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1130662	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	31742	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	110094	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2460282	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1240756	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	180000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	45000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2370000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2370000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1447722	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1447722	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2370	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1448	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	128044509	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	120105728	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-148192	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-139295	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118331653	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-97088422	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	9567034	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22879459	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12027316	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24120215	usd
CY2023	us-gaap	Revenues Revenues	733871	usd
CY2022	us-gaap	Revenues Revenues	495805	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12061422	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18496340	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10567111	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13796255	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	22628533	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	32292595	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-21894662	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-31796790	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	266188	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	26728	usd
CY2023	tffp	Change In Fair Value Of Note Receivable ChangeInFairValueOfNoteReceivable	385243	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	651431	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	26728	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21243231	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-31770062	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.85
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-26.49
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1792551	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1199191	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21243231	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-31770062	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-8897	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-90374	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21252128	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31860436	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	38737059	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	404555	usd
CY2022	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	11235626	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	110822	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4251833	usd
CY2022	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-90374	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-31770062	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	22879459	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	60265	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	108700	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5064722	usd
CY2023	tffp	Cash Paid For Fractional Shares Resulting From Reverse Stock Split CashPaidForFractionalSharesResultingFromReverseStockSplit	-2875	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2926291	usd
CY2023	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-8897	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21243231	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	9567034	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21243231	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-31770062	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2926291	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4251833	usd
CY2023	tffp	Interest Accrued On Note Receivable InterestAccruedOnNoteReceivable	111782	usd
CY2023	tffp	Fair Value Adjustmentof Note Receivable FairValueAdjustmentofNoteReceivable	-385243	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	747348	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	502480	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	388221	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	184272	usd
CY2023	tffp	Increase Decrease In Research And Development Tax Incentive Receivable IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable	259797	usd
CY2022	tffp	Increase Decrease In Research And Development Tax Incentive Receivable IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable	-751403	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1480729	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-181604	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	38382	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-577105	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	367093	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-412480	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-25000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	76000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-75465	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-47302	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16038195	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27342160	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	94750	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1551326	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-94750	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1551326	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	60265	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	404555	usd
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	108700	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	5064722	usd
CY2022	tffp	Net Proceeds From Issuances Of Common Stock And Warrants NetProceedsFromIssuancesOfCommonStockAndWarrants	11235626	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	110822	usd
CY2023	tffp	Payments To Settle Fractional Shares Resulting From Reverse Stock Split PaymentsToSettleFractionalSharesResultingFromReverseStockSplit	2875	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5013412	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11751003	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-14669	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-39874	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11134202	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17182357	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16612315	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33794672	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5478113	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16612315	usd
CY2023	tffp	Financing Obtained For Insurance Premiums FinancingObtainedForInsurancePremiums	914063	usd
CY2022	us-gaap	Consideration Received For Beneficial Interest Obtained For Transferring Financial Asset ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset	238021	usd
CY2022	tffp	Conversion Of Collaboration Receivable To Note Receivable ConversionOfCollaborationReceivableToNoteReceivable	1812975	usd
CY2022	tffp	Purchases Of Equipment Included In Accounts Payable PurchasesOfEquipmentIncludedInAccountsPayable	13400	usd
CY2022Q4	tffp	Underwriters Option Period From The Date Of Initial Public Offering UnderwritersOptionPeriodFromTheDateOfInitialPublicOffering	P45D
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-21200000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-31800000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27300000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5500000	usd
CY2023	tffp	Working Capital Surplus WorkingCapitalSurplus	5200000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118300000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Salvage Value Percentage PropertyPlantAndEquipmentSalvageValuePercentage	1	pure
CY2022Q4	us-gaap	Property Plant And Equipment Salvage Value Percentage PropertyPlantAndEquipmentSalvageValuePercentage	1	pure
CY2023Q4	us-gaap	Cash Cash	285827	aud
CY2023Q4	us-gaap	Cash Cash	194734	usd
CY2022Q4	us-gaap	Cash Cash	1028616	aud
CY2022Q4	us-gaap	Cash Cash	699977	usd
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	0.7	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	1.5	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	80625	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	119529	usd
CY2023	tffp	Research And Development Tax Percentage ResearchAndDevelopmentTaxPercentage	0.435	pure
CY2022	tffp	Research And Development Tax Percentage ResearchAndDevelopmentTaxPercentage	0.435	pure
CY2023Q4	tffp	Research And Development Tax Incentive Receivable ResearchAndDevelopmentTaxIncentiveReceivable	433852	usd
CY2022Q4	tffp	Research And Development Tax Incentive Receivable ResearchAndDevelopmentTaxIncentiveReceivable	186507	usd
CY2023	tffp	Reduction To Research And Development Expenses ReductionToResearchAndDevelopmentExpenses	259797	usd
CY2022	tffp	Reduction To Research And Development Expenses ReductionToResearchAndDevelopmentExpenses	274863	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	481556	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	346431	shares
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of condensed consolidated financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include the fair value of the convertible note receivable, stock-based compensation and warrants and the valuation allowance against deferred tax assets. Actual results could differ from those estimates.</span></p>
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	196044	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	83512	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1285586	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4430	usd
CY2023Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	914063	usd
CY2023Q4	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.0995	pure
CY2023	us-gaap	Interest Expense InterestExpense	14475	usd
CY2018Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	37080	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	31742	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	110094	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	115254	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	190719	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2023	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	88050	usd
CY2022	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	57300	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	91000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	38000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	129000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	14000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	115000	usd
CY2023	us-gaap	Payments For Fees PaymentsForFees	500000	usd
CY2023	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	15000000	usd
CY2023	us-gaap	Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed	1	pure
CY2023Q4	us-gaap	Notes Receivable Fair Value Disclosure NotesReceivableFairValueDisclosure	2310000	usd
CY2022Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	10.7	usd
CY2022Q4	tffp	Proceeds From Net Proceeds Underwriting Discounts And Offering Expenses ProceedsFromNetProceedsUnderwritingDiscountsAndOfferingExpenses	11200000	usd
CY2022Q4	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	213500	usd
CY2022Q4	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	32.25
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023Q3	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	18304	usd
CY2023Q3	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	7.81
CY2023Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q4	tffp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	144.75
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P4Y4M24D
CY2022	tffp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice	32.75
CY2022Q4	tffp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	40.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P4Y4M24D
CY2023	tffp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Range Of Exercise Price Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityRangeOfExercisePriceIssued	7.81
CY2023	tffp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Issued Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsIssuedWeightedAverageExercisePrice	7.81
CY2023	tffp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Range Of Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityRangeOfExercisePriceExpired	62.5
CY2023	tffp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expired Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredWeightedAverageExercisePrice	62.5
CY2023Q4	tffp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	42.38
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P4Y4M24D
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2926291	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	4251833	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	3800000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	22.92
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	92.75
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.42
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	71
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	115754	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	162
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	9932413	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	18256	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	92.75
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1692	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	65.5
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	15955	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	188.25
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	116363	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	162
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y5M15D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	24279	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	138837	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	22.92
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	21860	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	142.96
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	233340	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	74.63
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M28D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	107752	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	108.51
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y29D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	300000	shares
CY2022	us-gaap	Share Based Goods And Nonemployee Services Transaction Modification Of Terms Incremental Compensation Cost ShareBasedGoodsAndNonemployeeServicesTransactionModificationOfTermsIncrementalCompensationCost	200000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-5119585	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-7871979	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-29214	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-25908	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	453410	usd
CY2023	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	5174707	usd
CY2022	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	7418569	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17989784	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15321270	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3261950	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2384554	usd
CY2023Q4	tffp	Deferred Tax Assets In Amortization DeferredTaxAssetsInAmortization	4454248	usd
CY2022Q4	tffp	Deferred Tax Assets In Amortization DeferredTaxAssetsInAmortization	3437763	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	375916	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	175334	usd
CY2023Q4	tffp	Deferred Tax Assets Stock Compensation DeferredTaxAssetsStockCompensation	1527808	usd
CY2022Q4	tffp	Deferred Tax Assets Stock Compensation DeferredTaxAssetsStockCompensation	1029447	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	-77399	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	-173	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	27532307	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22348195	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27532307	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22348195	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0038	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0031	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0064	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0094	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0413	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0503	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2411	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2478	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	84366128	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	71906839	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4349267	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3179405	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	841000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	790000	usd
CY2023	tffp	Corporate Rate Percentage CorporateRatePercentage	0.15	pure
CY2023	us-gaap	Other Income OtherIncome	1000000000	usd
CY2023	tffp	Excise Tax Surcharge Percentage ExciseTaxSurchargePercentage	0.01	pure
CY2023	tffp	Valuation Allowance On Deferred Tax Assets ValuationAllowanceOnDeferredTaxAssets	1	pure
CY2023Q4	tffp	Uncertain Tax Positions UncertainTaxPositions	1087317	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	1087317	usd
CY2023Q4	tffp	Uncertain Tax Positions Begnning Balance UncertainTaxPositionsBegnningBalance	794851	usd
CY2023Q4	tffp	Additions For Tax Positions Related To Current Year AdditionsForTaxPositionsRelatedToCurrentYear	292466	usd
CY2023Q4	tffp	Uncertain Tax Positions Ending Balance UncertainTaxPositionsEndingBalance	1087317	usd
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1792551	shares
CY2022	tffp	Interest Accrued On Note Receivable InterestAccruedOnNoteReceivable		usd
CY2022	tffp	Fair Value Adjustmentof Note Receivable FairValueAdjustmentofNoteReceivable		usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2023	tffp	Net Proceeds From Issuances Of Common Stock And Warrants NetProceedsFromIssuancesOfCommonStockAndWarrants		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	tffp	Payments To Settle Fractional Shares Resulting From Reverse Stock Split PaymentsToSettleFractionalSharesResultingFromReverseStockSplit		usd
CY2022	tffp	Financing Obtained For Insurance Premiums FinancingObtainedForInsurancePremiums		usd
CY2023	us-gaap	Consideration Received For Beneficial Interest Obtained For Transferring Financial Asset ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset		usd
CY2023	tffp	Conversion Of Collaboration Receivable To Note Receivable ConversionOfCollaborationReceivableToNoteReceivable		usd
CY2023	tffp	Purchases Of Equipment Included In Accounts Payable PurchasesOfEquipmentIncludedInAccountsPayable		usd
CY2022	tffp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Range Of Exercise Price Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityRangeOfExercisePriceExercised
CY2022	tffp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
CY2023	tffp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Range Of Exercise Price Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityRangeOfExercisePriceExercised
CY2023	tffp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit		usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2023Q4	tffp	Decreases For Tax Positions Related To Prior Years DecreasesForTaxPositionsRelatedToPriorYears		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001733413

Files In Submission

Name	View Source	Status
0001213900-24-027185-index-headers.html	Edgar Link	pending
0001213900-24-027185-index.html	Edgar Link	pending
0001213900-24-027185.txt	Edgar Link	pending
0001213900-24-027185-xbrl.zip	Edgar Link	pending
ea0201339-10k_tffpharma.htm	Edgar Link	pending
ea0201339ex23-1_tffpharma.htm	Edgar Link	pending
ea0201339ex31-1_tffpharma.htm	Edgar Link	pending
ea0201339ex31-2_tffpharma.htm	Edgar Link	pending
ea0201339ex32-1_tffpharma.htm	Edgar Link	pending
ea0201339ex97-1_tffpharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ea0201339-10k_tffpharma_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tffp-20231231.xsd	Edgar Link	pending
tffp-20231231_def.xml	Edgar Link	unprocessable
tffp-20231231_lab.xml	Edgar Link	unprocessable
tffp-20231231_pre.xml	Edgar Link	unprocessable
tffp-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TFFP
TFF Pharmaceuticals, Inc. Stock $tffp

2024 Q1 Form 10-K Financial Statement

#000121390024027185 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TFFP TFF Pharmaceuticals, Inc. Stock $tffp

2024 Q1 Form 10-K Financial Statement

#000121390024027185 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TFFP
TFF Pharmaceuticals, Inc. Stock $tffp